|[January 17, 2014]
Vaxenta Inc. Presents at Leonhardt Ventures Technology Showcase
SAN DIEGO --(Business Wire)--
Vaxenta Biotechnologies presented at the Leonhardt Ventures Technology
Showcase on January 15th in San Francisco, CA (News - Alert). The company provided an
update on IND enabling studies in melanoma and colon cancer animal
models, as well as disclosed new data on safety studies.
Leonhardt Ventures has a track record of developing and commercializing
innovative technologies since 1982. The Leonhardt team pioneered
cardiovascular balloon catheters in the 1980's, stent grafts and
percutaneous heart valves in the 1990's and cardiac regenerative
medicine therapies in the 2000's. The conference showcased the Leonhardt
Ventures portfolio of healthcare innovations.
About Vaxenta Inc.
Vaxenta is a biotechnology company focused on development of novel
immunotherapeutic vaccines for the treatment of cancer. The company's
lead product, XenUvaX, leverages similarities between cancer and
pregnancy to selectively targt the three essential features of cancer:
a) angiogenesis; b) metastasis; and c) immune suppression. Currently the
company is in late stages of preclinical development, with plans to file
an IND to the FDA in Q3 2014 for treatment of melanoma.
Disclaimer: This news release may contain forward-looking
statements. Forward-looking statements are inherently subject to risks
and uncertainties, some of which cannot be predicted or quantified.
Future events and actual results could differ materially from those set
forth in, contemplated by, or underlying the forward-looking statements.
The risks and uncertainties to which forward-looking statements are
subject include, but are not limited to, the effect of government
regulation, competition and other material risks.
[ Back To TMCnet.com's Homepage ]